Histologic Alterations from Neoadjuvant Chemotherapy in High-Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation

Lucas, David R.; Kshirsagar, Malti; Biermann, J. Sybil; Hamre, Merlin; Thomas, Dafydd G.; Schuetze, Scott M.; Baker, Laurence H.

doi:10.1634/theoncologist.2007-0220

Cited by 66 publications

(57 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lower cellularity in investigated fields from those cases, with large acellular spaces between abnormal giant cells (morphology described by other authors in human glioma treated with radiotherapy [44] and in human treated sarcoma [45]) could be partially responsible for that. We wondered if analyzing the number of Ki67 positive cells by mm 2 instead of percent tumor cells would be helpful for clarification, and the results may be seen in Figure S7, in which the number of Ki67 positive cells/mm 2 is illustrated.…”

Section: Discussionmentioning

confidence: 74%

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

et al. 2017

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM using semi-supervised source extraction and single-slice Magnetic Resonance Spectroscopic Imaging (MRSI). Nevertheless, GBMs are heterogeneous and single-slice studies could prevent obtaining relevant information. The purpose of this work was to evaluate whether a multi-slice MRSI approach, acquiring consecutive grids across the tumor, is feasible for preclinical models and may produce additional insight into therapy response. Nosological images were analyzed pixel-by-pixel and a relative responding volume, the Tumor Responding Index (TRI), was defined to quantify response. Heterogeneous response levels were observed and treated animals were ascribed to three arbitrary predefined groups: high response (HR, n = 2), TRI = 68.2 ± 2.8%, intermediate response (IR, n = 6), TRI = 41.1 ± 4.2% and low response (LR, n = 2), TRI = 13.4 ± 14.3%, producing therapy response categorization which had not been fully registered in single-slice studies. Results agreed with the multi-slice approach being feasible and producing an inverse correlation between TRI and Ki67 immunostaining. Additionally, ca. 7-day oscillations of TRI were observed, suggesting that host immune system activation in response to treatment could contribute to the responding patterns detected.

show abstract

Section: Discussionmentioning

confidence: 74%

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…26,28,35 Such a distinction encompasses, in addition to tumor necrosis, the presence of fibrosis and acellular matrix as elements of nonviable tumor, and cumulatively represents treatment effect. In routine practice, a pathologist would presumably consider the entire area occupied by necrotic cells, acellular matrix, and loose fibrous tissue in estimating the extent of ''necrosis.''…”

Section: Discussionmentioning

confidence: 99%

“…Overall, there was a high level of concordance between the initial and final diagnoses (j ¼ .89; Supplemental Various histologic alterations associated with treatment effect were observed and were consistent with previously published descriptions (Figure 1). [27][28][29] An admixture of degenerating wispy osteoid matrix with empty lacunae, necrotic ghost cells, and edematous stroma with loose fibrous tissue was a commonly observed pattern of response. Other areas showed dense fibrosis or hyalinization, particularly prominent in fibroblastic osteosarcomas, whereas replacement of tumor by sheets of sclerotic acellular osteoid matrix was most common in osteoblastic osteosarcomas.…”

Section: Histologic Featuresmentioning

confidence: 99%

Histopathologic Features of Prognostic Significance in High-Grade Osteosarcoma

Chui

Kandel²,

Wong³

et al. 2016

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-In osteosarcoma treated with neoadjuvant chemotherapy the extent of tumor necrosis on resection is considered an indicator of treatment response, and this has been shown to correlate with survival in most but not all studies.Objective.-To identify additional histologic variables of prognostic significance in high-grade osteosarcoma.Design.-Slides of pretreatment biopsy and primary postneoadjuvant chemotherapy resections from 165 patients with high-grade osteosarcoma were reviewed. Univariate (Kaplan-Meier) and multivariate (Cox regression) analyses were performed to identify clinical and histomorphologic attributes associated with overall survival.Results.-Univariate analyses confirmed the prognostic significance of metastatic status on presentation, primary tumor size, anatomic site, and histologic subtype. Additionally, the identification of lymphovascular invasion, 10% or more residual viable tumor, and 10 or more mitoses per 10 high-powered fields assessed in posttreatment resections were associated with poor survival, retaining significance in multivariate analyses. Based on results from multivariate analysis, we developed a prognostic index incorporating primary tumor size and site, and significant histologic features assessed on resection (ie, lymphovascular invasion status, mitotic rate, and extent of viable tumor). This scoring system segregates patients into 3 risk categories with significant differences in overall survival and retained significance in an independent validation set of 42 cases.Conclusions.-The integration of clinical and microscopic features improves prognostication of patients with osteosarcoma.

show abstract

“…It can be presumed that the endoprosthestic group typically has closer tumor margins and thus requires wider surgical margins, which is why they are obvious candidates for the endoprosthesis and not the CS procedure. For those patients with histologic tumor data, response to chemotherapy was categorized using a modified Huvos score [18]. The Huvos score is a classification system that grades the histologic response of tumors to preoperative chemotherapy based on the percentage of tumor necrosis.…”

Section: Methodsmentioning

confidence: 99%

“…The Huvos score is a classification system that grades the histologic response of tumors to preoperative chemotherapy based on the percentage of tumor necrosis. We used a modified version of the original grading system by Lucas et al [18] with ''poor'' = ''C 50% viability,'' ''moderate'' = ''C 5% but \ 50% viability,'' and ''excellent'' = ''0 B 5% viability''. This was further modified to responders (\ 50% tumor viability) and nonresponders (C 50% tumor viability).…”

Section: Methodsmentioning

confidence: 99%

Megaprosthesis versus Condyle-sparing Intercalary Allograft: Distal Femoral Sarcoma

Zimel¹,

Cizik

Rapp³

et al. 2009

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Although functionally appealing in preserving the native knee, the condyle-sparing intercalary allograft of the distal femur may be associated with a higher risk of tumor recurrence and endoprosthetic replacement for malignant distal femoral bone tumors. We therefore compared the risk of local tumor recurrence between patients in these two types of reconstruction groups. We retrospectively reviewed 85 patients (mean age, 22 years; range, 4-82 years), 38 (45%) of whom had a condyle-sparing allograft and 47 (55%) of whom had endoprostheses. The minimum followup for both groups was 2 years (mean, 7 years; range, 2-19 years). Local recurrences occurred in 11% (five of 47) of the patients having implants versus 18% (seven of 38) of the patients having allografts. Using time to local recurrence as an end point, the Kaplan-Meier

show abstract

Histologic Alterations from Neoadjuvant Chemotherapy in High-Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation

Cited by 66 publications

References 25 publications

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

Histopathologic Features of Prognostic Significance in High-Grade Osteosarcoma

Megaprosthesis versus Condyle-sparing Intercalary Allograft: Distal Femoral Sarcoma

Contact Info

Product

Resources

About